Prof Hope Rugo speaks to ecancer about novel antibody-drug conjugates (ADCs) technologies for management of mBC.

She begins her discussion by exploring a study presented at SABCS 2022 involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulting in significant longer progression-free and overall survival.

Prof Rugo then explores the DESTINY-Breast04 trial. She explains trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast cancer, which highlights the clinical relevance of the HER2-low patient population and supports a need to redefine subgroups within HER2-negative breast cancers.

She concludes by discussing patritumab deruxtecan (HER3-DXd) and the next step for this trial.

свернуть